An established drug for recurrent multiple myeloma might effectively be repurposed to improve the survival and day-to-day lives of patients with devastating sickle cell disease, according to revealing new research by a Feinstein Institute for Medical Research scientist.
The study, by Lionel Blanc, PhD, an assistant investigator at the Feinstein Institute, will be published Dec. 17 in the journal Blood. Dr. Blanc’s research, performed in collaboration with the New York Blood Center, Yale School of Medicine and University of Montpellier in France, was the first to identify how the drug pomalidomide increases production of fetal hemoglobin, known to interfere with the so-called “sickling” of red blood cells implicated in sickle cell disease (SCD).
Illuminating pomalidomide’s mechanism of action offers proof of concept that the US Food and Drug Administration (FDA)-approved medication could potentially be used to treat SCD, representing better outcomes compared to current drug treatment for the 100,000 Americans with SCD, an inherited disorder causing poor oxygen delivery, organ damage and even death.
“We knew the drug would make fetal hemoglobin, but we didn’t know to what extent or how. That was the goal of the study,” explained Dr. Blanc, also an assistant professor of molecular medicine and pediatrics at Hofstra North Shore-LIJ School of Medicine and an Allied World St. Baldrick’s Scholar.
“We can also say something else – that hydroxyurea, the only FDA-approved drug for sickle cell anemia, was less effective than pomalidomide and appeared to act through a different mechanism of action,” he added. “The current therapy is good, but not everyone responds equally to hydroxyurea, and what we hope with pomalidomide is to improve this.”
Pomalidomide, a derivative of thalidomide used in advanced cases of the cancer multiple myeloma, works by killing malignant plasma cells. But Dr. Blanc and his colleagues demonstrated in the new research, performed on stem cells taken from five SCD patients and 120 normal controls, how pomalidomide also generated fetal hemoglobin, the fetal version of the protein in red blood cells that carries oxygen to body tissues.
In patients with congenital conditions producing anemia such as SCD and beta-thalassemia, fetal hemoglobin is normal, but adult hemoglobin – produced after birth – is abnormal. Therefore, reversing their production of adult hemoglobin back to fetal hemoglobin can reverse the course of their disease.
In addition to the 100,000 US residents with SCD, the condition also affects millions globally. “I would remind people that anemia impacts 1.6 billion people worldwide, making it a global economic burden,” Dr. Blanc notes.
Dr. Blanc and his colleagues in the Division of Hematology/Oncology at Cohen Children’s Medical Center of New York plan to launch a clinical trial in the near future in collaboration with other institutions to test pomalidomide, which is taken orally, in young adults with SCD.
Currently, the only potential cures for SCD are gene therapy, still in the experimental stage, or stem cell transplant, but these resource-intense treatments aren’t available to the vast majority of patients, particularly in the developing world.
“Our hope is to alleviate the symptoms of sickle cell disease by using a pill that could be made available to almost all patients, worldwide,” Dr. Blanc said.
The Latest on: Sickle Cell Disease
via Google News
The Latest on: Sickle Cell Disease
- Why So Many Biotechs Are Scrambling to Develop a Drug for the Same Rare Diseaseon February 23, 2020 at 11:32 am
Another potential reason why biotechs are attracted to beta-thalassemia, though, is that it's not the only disease that is caused by mutations in the HBB gene. Sickle cell disease (SCD) is a related ...
- Sickle cell and depressionon February 21, 2020 at 6:08 pm
Tola DehindeSickle cell disease is a group of blood disorders. It can cause anemia which if severe can reduce mobility. It may also allow small vessels to become blocked causing pain in muscles and ...
- What to know about sickle cell diseaseon February 20, 2020 at 5:55 pm
Sickle cell disease is a group of genetic disorders that affect hemoglobin. Hemoglobin is a molecule in red blood cells that carries oxygen and delivers it to tissues. Sickle cell disease can be life ...
- GBT Accepting Proposals for 2020 ACCEL Grants to Support Novel Access-to-Care Programs for People Living with Sickle Cell Diseaseon February 20, 2020 at 5:00 am
Global Blood Therapeutics, Inc. (GBT) GBT, -0.08% today announced that it is accepting proposals for its Access to Excellent Care for Sickle Cell Patients (ACCEL) Grant Program, which provides grant ...
- FORMA Therapeutics Announces FT-4202 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Sickle Cell Diseaseon February 20, 2020 at 4:05 am
The FDA defines a "rare pediatric disease" as a rare disease in which the serious or life-threatening manifestations primarily affect individuals from age zero to 18. 2 About Sickle Cell Disease ...
- Dr C. Patrick Carroll on Biases Impacting African Americans With Sickle Cell Disease and Painon February 19, 2020 at 7:37 am
Patients with sickle cell disease already face suspicion and biases based on their need for opioids, and African American patients also face additional racial biases, said C. Patrick Carroll, MD, ...
- Imara Reveals IPOs Plan as Sickle Cell Drug Advances in the Clinicon February 18, 2020 at 10:46 am
Sickle cell disease research is seeing a flurry of activity with several companies currently testing therapies for the genetic blood disorder and one company recently receiving FDA approval. Imara ...
- Sickle Cell Disease: After Years Of Neglect Some Promise For Suffererson February 17, 2020 at 8:23 am
In the past five years there has very encouraging news on the sickle cell disease drug development front. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, there ...
- Plea to Bahrain MPs by sickle cell society on waiting time for female patientson February 16, 2020 at 2:41 am
The GDN previously reported that women had to wait for up to eight hours at a specially designated area for sickle cell disease at the hospital, while men were able to see a doctor within 25 minutes.
- eGFR decline among black patients with sickle cell trait, diseaseon February 14, 2020 at 8:29 am
Sickle cell trait and disease were associated with a faster decline in eGFR in black patients, according to a study published in the Journal of the American Society of Nephrology. “Despite studies ...
via Bing News